Table 1.

Patients’ characteristics

	n = 97
Gender
Male	56 (57.7%)
Female	41 (42.3%)
Median age at diagnosis (range)	55 (25–80)
WHO grade
WHO II	21 (21.7%)
WHO III	8 (8.2%)
WHO IV	68 (70.1%)
IDH mutation
IDH mutated	27 (27.8%)
IDH wildtype	70 (72.2%)
MGMT promoter methylation
Methylated	23 (23.7%)
Unmethylated	36 (37.1%)
Unknown	38 (39.2%)
Diagnosis according to WHO 2016 classification
Diffuse astrocytoma, IDH-mt	11 (11.3%)
Gemistocytic astrocytoma, IDH-mt	1 (1.0%)
Anaplastic astrocytoma, IDH-mt	2 (2.1%)
Diffuse astrocytoma, IDH-wt	2 (2.1%)
Oligodendroglioma, IDH-mt, 1p19q-codeleted	7 (7.2%)
Anaplastic oligodendroglioma, IDH-mt, 1p19q-codeleted	6 (6.2%)
Glioblastoma, IDH-wt	68 (69.4%)